A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hybrobromide [d6-DM]/quindine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type. Save

Date Added
March 28th, 2017
PRO Number
Pro00064742
Researcher
Olga Brawman-mintzer
Keywords
Alzheimers
Summary

The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer's type.

Institution
MUSC
Recruitment Contact
Keaveny Donovan
843-577-5011,extension 5188
keaveny.donovan@va.gov

A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder Save

Date Added
March 24th, 2015
PRO Number
Pro00042473
Researcher
Olga Brawman-mintzer
Keywords
Depression, Drug Studies, Mental Health
Summary

Major depressive disorder (MDD) is a mental illness in which affected individuals have low mood with low self-esteem, and loss of interest or pleasure in normally enjoyable activities. It is a long-term illness for many subjects and maintenance therapy is recommended to prevent relapse in subjects with recurrent depression.
The purpose of this study is to test the efficacy and safety of doses of vortioxetine capsules (5, 10 or 20 mg/day) compared with placebo (a non-active capsule/ ?dummy drug?) in preventing relapse in people with acute recurrent MDD.

Institution
MUSC
Recruitment Contact
Olga Brawman-Mintzer
843-724-2945
mintzero@musc.edu

Change_preferences

-- OR --

Create_login